Enhancing effect of an inhibitor of nitric oxide synthesis on Bacillus Calmette-Guerin-induced macrophage cytotoxicity against murine bladder cancer cell line MBT-2 in vitro

Japanese Journal of Cancer Research

Volumn 91, Issue 5, 2000, Pages 534-542

  Yamada, Hiroshi ^a   Matsumoto, Sohkichi ^b   Matsumoto, Tetsuro ^a   Yamada, Takeshi ^b   Yamashita, Uki ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

BCG; Bladder cancer; Cytotoxicity; Macrophage; Nitric oxide

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG POTENTIATION; FEMALE; IN VITRO STUDY; LYMPHOCYTE DEPLETION; MACROPHAGE; MOUSE; NONHUMAN; PERITONEAL EXUDATE CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0034120679     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2000.tb00978.x     Document Type: Article

References (42)

1. Kavoussi, L. R., Torrence, R. J., Gillen, D. P., Hudson, M., Haaff, E. O., Dresner, S. M., Ratliff, T. L. and Catallona, W. J. Result of 6 weekly intravesical bacillus Calmette Guerin instillations on the treatment of superficial bladder tumors. J. Urol., 139, 935-940 (1988).
2. Bohle, A., Gerdes, J., Ulmer, A. J., Hofstetter, A. G. and Flad, H. D. Effect of local bacillus Calmette Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J. Urol., 144, 53-58 (1990).
3. Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. and Smyth, J. F. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J. Urol., 147, 1636-1642 (1992).
4. Peuchmaur, M., Benott, G., Vieillefond, A., Chevalier, A., Lemaigre, G., Martin, E. D. and Jardin, A. Analysis of mucosal bladder leukocyte subpopulation in patients treated with intravesical bacillus Calmette Guerin. Urol. Res., 17, 299-303 (1989).
5. De Boer, E. C., De Jong, W. H., Van Der Meijiden, A. P. M., Steerenberg, P. A., Witjes, J. A., Vegt, P. D. J., Debruyne, F. M. J. and Ruitenberg, E. J. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette Guerin. Cancer Immunol. Immunother., 33, 411-416 (1991).
6. De Boer, E. C., De Jong, W. H., Steerenberg, P. A., Aarden, L. A., Tetteroo, E., De Groot, E. R., Van Der Meijiden, A. P. M., Vegt, P. D. J., Debruyne, F. M. J. and Ruitenberg, E. J. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumor necrosis factor during intravesical immunotherapy with bacillus Calmette Guerin. Cancer Immunol. Immunother., 34, 306-312 (1992).
7. Bohle, A., Nowc, C. H., Ulmer, A. J., Musehold, J., Gerdes, J., Hostetter, A. G. and Flad, H. D. Elevations of cytokines of interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette Guerin immunotherapy. J. Urol., 144, 59-63 (1990).
8. Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D. and Smyth, J. F. Radioimmunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J. Urol., 144, 1248-1251 (1990).
9. Matsumoto, H., Suzuki, K., Tsuyuguchi, K., Tanaka, E., Amitani, R., Maeda, A., Yamamoto, K., Sasada, M. and Kuze, F. Interleukin-12 gene expression in human monocyte-derived macrophages stimulated with Mycobacterium bovis BCG; cytokine regulation and effect of NK cells. Infect. Immun., 65, 4405-4410 (1997).
10. Belosevic, M., Finbloom, D. S., Meltzer, M. S. and Nacy, C. A. IL-2: a cofactor for induction of activated macrophage resistance to infection. J. Immunol., 145, 831-839 (1990).
11. Flesch, I. E. A. and Kaufmann, S. H. E. Attempt to characterize the mechanisms involved in Mycobacterial growth inhibition by gamma-interferon-activated bone marrow macrophages. Infect. Immun., 56, 1464-1471 (1988).
12. Green, S. J., Scheller, L. F., Marletta, M. A., Seguim, M. C., Klotz, F. W., Slayer, M., Nelson, B. J. and Nacy, C. A. Nitric oxide: cytokine-regulation of nitric oxide in host resistance to intracellular pathogens. Immunol. Lett., 43, 87-94 (1994).
13. Nozaki, Y., Hasegawa, Y., Ichiyama, S., Nakushima, I. and Shimokata, K. Mechanism of nitric oxide-dependent killing of Mycobacterium bovis BCG in human alveolar macrophages. Infect. Immun., 65, 3644-3647 (1997).
14. Andrew, W. T. R. Counter-regulation of T helper I cell proliferation by nitric oxide and interleukin-2. Biochem. Biophys. Res. Commun., 233, 14-19 (1997).
15. Wei, X.-Q., Charles, I. G., Smith, A., Ure, J., Feng, G. J., Huang, F. P., Xu, D., Muller, W., Moncada, S. and Liew, F. Y. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature, 375, 408-411 (1995).
16. Bauer, H., Jung, T., Tsikas, D., Stichtenoth, D. O., Frolich, C. and Neumann, C. Nitric oxide inhibits the secretion of T helper 1-and T helper 2-associated cytokines in activated human T cells. Immunology, 90, 205-211 (1997).
17. Mickey, D. D., Mickey, G. H., Murphy, W. M., Niell, H. B. and Soloway. M. S. In vitro characterization of four N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT) induced mouse bladder tumors. J. Urol., 127, 1233-1237 (1982).
18. Flick, D. A. and Gifford, G. E. Comparison of in vitro cell cytotoxicity assays for tumor necrosis factor. J. Immunol. Methods, 68, 167-172 (1984).
19. 15N]-nitrate in biological fluids. Anal. Biochem., 126, 131-141 (1982).
20. Melker, M. S., Tucker, R. W., Sanford, K. K. and Leonard, E. J. Interaction of BCG-activated macrophages with neoplastic and non-neoplastic cell lines in vitro: quantitation of the cytotoxic reaction by release of tritiated thymidine from pre-labelled target cells. J. Natl. Cancer Inst., 54, 1177-1184 (1975).
21. Meltzer, M. S. and Stevenson, M. M. Macrophages function in tumor-bearing mice: tumoricidal and chemotactic responses of macrophages activated by infection with Mycobacterium bovis, strain BCG. J. Immunol., 118, 2176-2181 (1977).
22. Tagliabue, A., Montovani, A., Kilgallen, M., Herberman, R. B. and McCoy, J. L. Natural cytotoxicity of mouse monocytes and macrophages. J. Immunol., 122, 2363-2370 (1979).
23. Mizutani, Y., Nio, Y., Fukumoto, M. and Yoshida, O. Effect of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lines and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer, 69, 537-545 (1992).
24. Kelley, D. R., Ratliff, T. L., Catalona, W. J., Shapiro, A., Lage, J. M., Bauer, W. C., Haaff, E. O. and Dresner, S. M. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J. Urol., 134, 48-53 (1985).
25. Matsuo, K., Yamaguchi, R., Yamazaki, A., Tasaka, H. and Yamada, T. Cloning and expression of the Mycobacterium bovis BCG gene for extracellular alpha antigen. J. Bacteriol., 170, 3847-3854 (1988).
26. Aung, H., Toossi, Z., Wisnieski, J. J., Wallis, R. S., Cuip, L. A., Phillips, N. B., Phillips, M., Averill, L. E., Daniel, T. M. and Ellner, J. J. Induction of monocyte expression of tumor necrosis factor a by the 30-kD α antigen of Mycobacterium tuberculosis and synergism with fibronectin. J. Clin. Invest., 98, 1261-1268 (1996).
27. Orme, I. M., Roberts, A. D., Griffin, J. P. and Abrams, J. S. Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection. J. Immunol., 151, 518-525 (1993).
28. Boom, W. H., Wallis, R. S. and Chervenak, K. A. Human Mycobacterium tuberculosis-reaclne CD4+ T cell clones: heterogeneity in antigen recognition, cytokine production, and cytotoxicity for mononuclear phagocytes. Infect. Immun., 59, 2737-2743 (1991).
29. Turner, J. and Dockrell, H. M. Stimulation of human peripheral blood mononuclear cells with Mycobacterium bovis BCG activates cytolytic CD8+ T cells in vitro. Immunology: 87, 339-342 (1996).
30. Lalvan, A., Brookes, R., Wilkinson, R. J., Malin, A. S., Pathan, A. A., Andersen, P., Dockrell, H., Pasvol, G. and Hill, A. V. S. Human cytolytic and Interferon γ-setreting CD8+ T lymphocytes specific for Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA, 95, 270-275 (1998).
31. Yang, J., Kawamura, I., Zhu, H. and Mitsuyama, M. Involvement of natural killer cells in nitric oxide production by spleen cells after stimulation with Mycobacterium bovis BCG: study of the mechanism of the different abilities of viable and killed BCG. J. Immunol., 155, 5728-5735 (1995).
32. Fenton, M. J., Vermeulen, M. W., Kim, S., Burdick, M., Strieter, R. M. and Kornfeld, H. Induction of gamma Interferon production in human alveolar macrophages by Mycobacterium tuberculosis. Infect. Immun., 65, 5149-5156 (1997).
33. Wang, J., Wakeham, J., Harkness, R. and Xing, Z. Macrophages are a significant source of type 1 cytokines during mycobacterial infection. J. Clin. Invest., 103, 1023-1029 (1999).
34. Molloy, A., Laochumroonvorapong, P. and Kaplan, G. Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guerin. J. Exp. Med., 180, 1499-1509 (1994).
35. Flesch, I. E. A., Hess, J. H., Huan, G. S., Aguet, M., Rothe, S. J., Bluethmann, H. and Kaufmann, S. H. E. Early interleukin 12 production by macrophages in response to Mycobacterial infection depends on interferon γ and tumor necrosis factor α. J. Exp. Med., 181, 1615-1621 (1995).
36. Sano, C., Sato, K., Shimizu, T., Kajitani, H., Kawauchi, H. and Tomioka, H. The modulating effects of proinflammatory cytokines interferon-gamma (IFN-γ) and tumor necrosis factor-alpha (TNF-α), and immunoregulating cytokines IL-10 and transforming growth factor-beta (TGF-β), on anti-microbial activity of murine peritoneal macrophages against Mycobacterium avium-intracellulare complex. Clin. Exp. Immunol., 115, 435-442 (1999).
37. Li, J., Bombeck, C. A., Van, S., Kim, Y. M. and Billiar, T. R. Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes. J. Biol. Chem., 274, 17325-17333 (1999).
38. Liu, L. and Stamler, J. S. NO: an inhibitor of cell death. Cell Death Differ., 6, 937-942 (1999).
39. Adams, D. O. and Mario, P. A. Evidence for a multistep mechanism of cytolysis by BCG-activated macrophages; the interrelationship between the capacity for cytolysis, target binding and secretion of cytolytic factor. J. Immunol., 126, 981-987 (1981).
40. Keller, R., Geiges, M. and Keist, R. L-Arginine-dependent reactive nitrogen intermediates as mediator of tumor cell killing by activated macrophages. Cancer Res., 50, 1421-1425 (1990).
41. Medot-Pirenne, M., Heilman, M. J., Saxena, M., McDermott, P. E. and Mills, C. D. Augmentation of an antitumor CTL response in vivo by inhibition of suppressor macrophage nitric oxide. J. Immunol., 163, 5877-5882 (1999).
42. Koblish, H. K., Hunter, C. A., Wysocka, M., Trinchieri, G. and Lee, W. M. F. Immune suppression by recombinant interleukin (rIL)-12 involves Interferon γ induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J. Exp. Med., 188, 1603-1610 (1998).